Erin Niehaus
Partner, DigitalDx Ventures. On 1 show, 1 appearance. The Shows tab opens the full record on each.
investoranalystdigitaldxventures.com/erin-niehaus.html ↗
At DigitalDx Ventures, Niehaus focuses on early-stage investments in healthcare, artificial intelligence, and early disease detection, alongside managing wealth for tech executives at Savvy Advisors. Her career spans over two decades in finance and private banking, including roles at J.P. Morgan Private Bank, Bordeaux Wealth Advisors, and Jennison Associates.
1shows
1appearances
15statements
3resolved
2supported
0contradicted
67%fully supported
Everything Erin Niehaus said on any show that made the record, most notable first. Each card names its show and opens the statement there.
Niehaus: AI will shift toward verticalized applications rather than bust
“Part of what I see happening, and I don't necessarily think it's going to be a bust, but I do feel like there's going to be a much more verticalized focus on where AI helps the productivity the most”
Niehaus: LLMs dominate early AI phase due to tangible productivity gains
“I think we're in the first phase where these Big LLMs are getting most of the airspace because the productivity is so tangible right now.”
Niehaus: Oxford Cancer Analytics Enables Liquid Lung Cancer Biopsies via Blood Tests
“We have a company coming out of Oxford, Oxford Cancer Analytics, that can do a blood test and do a liquid biopsy with blood, so you don't have to go into the hospital and be admitted, you don't have to collapse your lung, and the ROI on that kind of a thing sa…”
Niehaus: AI will unleash personalized medicine through multi-demographic pattern matching
“Personalized medicine is one of those things where it's a knowable fact. AI is one of the tools that will unleash that pattern matching for amounts of data sets, and we see it all the time in our companies. So many of them have to have thousands of samples to …”
Niehaus: DigitalDX has a woman on every portfolio company board
“We do have a woman on every board of every company that we have just cause we do believe in the ability to have different points of view and our boards reflect The population that we're serving in the healthcare space.”
Niehaus: DigitalDX Backs Startup Detecting Alzheimer's 10 Years Early via Eye Scans
“We have a company that does an eye scan for Alzheimer's 10 years before you see it.”
Niehaus: DigitalDX Uses Proprietary AI To Filter 100 Monthly Pitches To Four
“We have internally created a proprietary AI screening model for diligence, so, I mean, we probably see a hundred companies a month-ish. How do you whittle that down to the four that you're going to diligence? Right? So we have a quantitative screening that we …”
Niehaus: DigitalDX's thesis treats the human body as a big data problem
“Our thesis, our investment thesis, is that the human body is a big data problem”
Niehaus: DigitalDX Portfolio Company Biotia Tested NYC Sewer Water For COVID
“One of our portfolio companies, his name is Biosha. You may recall during COVID in New York City, they were testing the sewer water to see if COVID was in the water, and people were using that test to see if COVID was still spreading. So that came out of Weill…”
Niehaus: DigitalDX works with Mayo Clinic, Johns Hopkins, and Vanderbilt
“We meet with all the leaders in healthcare, like we were, we're with Mayo, we're with Johns Hopkins, like all the different people leading the charge, and we actually just did something, ah, the Five Lakes, which is in the Five Lakes region for all the univers…”
Niehaus: DigitalDX targets 10% ownership at exit
“We want to own 10% at exit, and so we really believe, and we see so many amazing ideas coming out of labs.”
Niehaus: DigitalDX Uses 25 Experts In Residence For Deal Sourcing and Diligence
“We have about 25 experts in residence who have had great careers and really just believe in our thesis. So they help us source deals and then diligence deals. So, for example, the former chief scientist at Myriad Genetics one of our partners is David Kirk, who…”
Niehaus: DigitalDX Backs Startup Developing Urine Test for Kidney Rejection
“One of our companies does a urine test to determine if you're going to reject a kidney from transplant.”
Niehaus: DigitalDX Invests in AI Healthcare and Non-Invasive Disease Detection
“DigitalDX is a pre-seed, seed investor. We focus on the intersection of AI and healthcare, and our main focus for an investment perspective is early non-invasive detection of large-scale diseases, cancers, Infectious diseases and cognitive diseases like Alzhei…”
One line per show, most statements first. The link opens Erin's full record on that show: the calibration, argument clarity, speaking style and every statement made there.
| Show | Role there | Eps | Statements | Record | |
|---|---|---|---|---|---|
 INNOVATORS & INVESTORSLEDGER | Partner, DigitalDx Ventures | 1 | 15 | 67% 2/3 | full record on Innovators & Investors → |